Viking Therapeutics (VKTX)
Develops clinical-stage therapies for obesity, metabolic and endocrine disorders.
Something off on this page? Send us feedback.
Drug candidates target obesity, metabolic and endocrine disorders. The pipeline spans injectable and oral VK2735, plus VK2809, VK0214, VK5211 and DACRA programs.
Clinical development focuses on metabolic and endocrine therapies, led by injectable and oral VK2735 for obesity. Other named programs include VK2809 for lipid and metabolic disorders, VK0214 for X-linked adrenoleukodystrophy, VK5211, and DACRA candidates for obesity and metabolic disease.
Viking is a clinical-stage biopharmaceutical company based in San Diego, with subsidiaries in Australia and Ireland and worldwide rights to several Ligand assets. Its pipeline combines licensed technology with internally developed programs.
Clinical trials and regulatory interactions shape program advancement. Viking has a manufacturing and supply agreement for VK2735 and is building commercial capabilities. Several program assets remain materially dependent on Ligand licenses.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 21, 2026 | Oppenheimer | Reiterate | Rating: —Target: $138 | Target: $100 |
| May 28, 2026 | Lake Street | Target | Target: — | Target: $89 |
| May 27, 2026 | Truist Financial | Target | Target: $75 | Target: $83 |
| Apr 30, 2026 | Morgan Stanley | Target | Target: $99 | Target: $95 |
| Apr 30, 2026 | Cantor Fitzgerald | Reiterate | Rating: —Target: $105 | Target: $100 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $501.7M · Total debt $4.1M · Total assets $521.9M · Shareholders' equity $408.3M
- Revenue
- $0
- Operating income
- −$132.6M
- Net income
- −$128.0M
No dividends on record.
| Institutions | 65.57% | 76.48M shares | |
|---|---|---|---|
| 471 holders · as of Jun 30, 2026 | |||
| Insiders | 2.96% | 3.45M shares | |
| 10 holders · as of Aug 7, 2026 | |||
| Other | 31.47% | 36.71M shares | |
| remainder | |||
116.65M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 5.43% | 6.34M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 5.31% | 6.19M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.81% | 5.61M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.33% | 5.05M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 3.84% | 4.48M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 29, 2026 | Marianna Mancini | officer: Chief Operating Officer | −18,217 | $33.47 |
| Jul 29, 2026 | Greg Zante | officer: Chief Financial Officer | −21,217 | $33.47 |
| Jul 29, 2026 | Brian Lian | director, officer: President & CEO | −148,517 | $33.32 |
| Mar 10, 2026 | Neil William Aubuchon | officer: Chief Commercial Officer | +4,475 | $33.50 |
| Jan 2, 2026 | Matthew W. Foehr | director | −16,000 | $35.11 |
- Eli Lilly
Marketed dual agonist plus oral GLP-1 obesity medicines
- Novo Nordisk (ADR)
Marketed semaglutide and next-generation obesity platform
- Madrigal Pharmaceuticals
Approved liver-directed THR-beta therapy for MASH
- Amgen
Phase 3 antibody-peptide obesity medicine with infrequent dosing
- Altimmune
GLP-1/glucagon dual agonist in Phase 3-planned MASH
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Viking Therapeutics | $37.72 | +25.30% | $3.51B | — | — | — | — |
| Eli Lilly | $1,150.74 | −1.15% | $1.10T | 39.1 | 28.5 | 13.8 | +47.7% |
| Novo Nordisk (ADR) | $39.48 | −0.78% | $176.83B | 9.9 | 16.3 | 3.5 | +1.3% |
| Madrigal Pharmaceuticals | $522.31 | −1.73% | $12.06B | — | — | 9.4 | +71.2% |
| Amgen | $412.00 | +4.78% | $212.19B | 24.4 | 16.8 | 5.6 | +9.7% |
| Altimmune | $3.39 | +3.52% | $635.9M | — | — | 20,513.9 | +820.0% |
| Median | 24.4 | 16.8 | 9.4 | +47.7% |